APLUSA

🌍 #WorldPsoriasisDay | On this World Psoriasis Day, we’re sharing key insights from APLUSA's Targeted Biologics SyndiTrack™, gathered from dermatologists in France in Q2 2024. 💡Did you know that 12% of psoriasis patients (excluding psoriatic arthritis cases) treated with targeted therapies experience depression? Additionally, 24% of these patients are affected by overweight or obesity. Interested in learning more about our Psoriasis SyndiTrack™ ? Contact us 👉 https://lnkd.in/epdj_Cj5 Source: APLUSA Biologics synditrack among dermatologists in France, collected data in Q2.2024.

🎗 Pink October - Evolving Treatment Landscape in HER2+ Metastatic Breast Cancer (mBC HER2+). At APLUSA, we’re dedicated to bringing forward the voices of patients battling HER2+ breast cancer. Our Social Media Listening database captures key insights into the patient experience, highlighting the impact of evolving treatments and the personal stories of resilience. Want to learn more or get in touch with our experts? 👉 https://lnkd.in/eaN8q7ng #PinkOctober #BreastCancerAwareness #HER2Positive #PatientStories #Healthcare

🎗 Pink October : Evolving Treatment Landscape in HER2+ Metastatic Breast Cancer (mBC HER2+). APLUSA continues its commitment to understanding and supporting the breast cancer community. Our latest data from the mBC HER2+ syndiTrack real-world database reveals key insights into patient characteristics, comorbidities, and the evolving treatment landscape for HER2+ breast cancer. 💡 Did you know? The majority of HER2+ breast cancer patients fall between the ages of 55 and 75, with significant disease burdens such as bone and liver metastases. Want to learn more or get in touch with our experts? 👉 https://lnkd.in/eaN8q7ng #PinkOctober #BreastCancerAwareness #HER2Positive

🎗 Pink October: Evolving Treatment Landscape in HER2+ Metastatic Breast Cancer (mBC HER2+) As we recognize Breast Cancer Awareness Month, we're highlighting the rapid advances in HER2+ mBC treatments, offering new hope to patients through innovative therapies. Targeted therapies, personalized medicine, and immunotherapy are transforming HER2+ metastatic breast cancer treatment. Our recent data shows Antibody-Drug Conjugates (ADCs) like trastuzumab deruxtecan are dominant in second-line therapy, while Tyrosine Kinase Inhibitors (TKIs) such as tucatinib are common in third-line treatments. Want to learn more or get in touch with our experts? 👉 https://lnkd.in/eaN8q7ng #PinkOctober #BreastCancerAwareness #HER2Positive

🌟 Join us at #ISPOR2024 in Barcelona! 🌟 We are thrilled to announce that our team, led by Stéphane DENIAU, NIS Business Unit Director, will be attending ISPOR 2024 in Barcelona from November 17–20! Meet us at Booth #703. Let’s connect and discuss how we can leverage our expertise in #RWE to fuel informed decisions and support impactful outcomes for your projects. 📅 November 17–20, 2024 | Barcelona 📍 ISPOR 2024 – Booth #703 Don’t miss the chance to meet us! 🤝 ISPOR—The Professional Society for Health Economics and Outcomes Research Christine Maï Marion VOUTE #ISPOR2024 #RealWorldEvidence #EvidenceBasedStrategy #PatientCare

📰 #Newsletter | Discover SMML, our newsletter dedicated to Multiple Myeloma! A selection of new articles, PR releases or digital opinion leaders, discover an overview of what is happening every month around multiple myeloma in terms of medical developments. Sign up to discover previous newsletters and to receive upcoming ones! 👉 https://lnkd.in/ehTByMNt #marketresearch #healthcare #MultipleMyeloma #MM

🌍 #APLUSAlife | 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟬𝘁𝗵 𝗶𝘀 𝗪𝗼𝗿𝗹𝗱 𝗠𝗲𝗻𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗮𝘆. This year’s theme, "Mental Health at Work," chosen by the World Health Organization, highlights the importance of this issue. With 60% of the global population in the workforce, it’s crucial to take action to enhance mental well-being in the workplace and prevent risks related to professional stress. Everyone deserves access to proper care and a healthy, inclusive work environment. #MentalHealth #MentalHealthAtWork #WorkplaceWellbeing

🎗️#APLUSALife | #𝗣𝗶𝗻𝗸𝗢𝗰𝘁𝗼𝗯𝗲𝗿 October is Breast Cancer Awareness Month, a time dedicated to raising awareness about the risks of breast cancer and supporting medical research to combat this critical health issue. At APLUSA, we proudly stand with millions of women and their families worldwide who are affected by breast cancer. Together, we can continue to share knowledge, support research, and help improve outcomes for women everywhere. #BreastCancerAwareness #SupportResearch

🚀 Nous sommes honorés d’être reconnus parmi les meilleures études de marché spécialisées 2024 dans le guide Santé, Pharmacie & Biotechnologies de Décideurs Innovation! Merci à Leaders League pour cette distinction, qui reflète l'expertise d'APLUSA et notre engagement dans l'innovation du secteur.   #Innovation #Santé #Pharmacie #Experts

🚀 APLUSA is proud to join AFCROs, driving innovation in clinical research! We bring our expertise in #RealWorldData and market insights to enhance clinical trial data, focusing on accuracy and actionable outcomes. With a long history in non-interventional studies, patient-centricity remains at the core of our work. Through our global network and healthcare market research expertise, we provide strategic support for medical affairs and market access, strengthening partnerships and shaping the future of clinical trials. Stéphane DENIAU #ClinicalResearch #Innovation #PatientCentricity #RWD #Healthcare